For instance, a cohort study of 116 patients with DLBCL in a third-line setting identified risk factors such as ECOG-PS ≥ 2, stage III/IV disease, ≥2 extranodal sites, elevated LDH, increased C-reactive protein (CRP), high IPI at the time of decision (TD) and treatment (TT), and bulky mass [36]. This evidence concerns the gene CRP and diffuse large B-cell lymphoma.